Company Overview - Integer Holdings Corporation is a medical device contract development and manufacturing company, known for its brands Greatbatch Medical and Lake Region Medical [1] - The company specializes in a range of medical applications, particularly in Cardio & Vascular, offering components and devices for various procedures including interventional cardiology and electrophysiology [1] Recent Developments - Irenic Capital Management has acquired a stake of over 3% in Integer Holdings and is advocating for a board refreshment and the exploration of a potential sale of the company [3][6] - Integer's share price has declined nearly 40% over the past year, primarily due to disappointing market demand for specific products, leading to reduced orders from original equipment manufacturers (OEMs) [4][5] Market Position and Challenges - Integer is the largest publicly traded pure-play medical device CDMO, facing limited investor understanding and coverage due to its unique market position [4][6] - The company typically targets organic growth of 6% to 8%, but projections for 2026 have been revised to a range of -2% to 2% [5] Strategic Considerations - Irenic Capital suggests that a sale could be beneficial, as private buyers could conduct thorough due diligence on Integer's products and contracts, which is challenging in a public setting [6][7] - Integer's management previously explored strategic alternatives in 2024, receiving bids at a premium to the share price, indicating potential interest from private equity [7] Board Composition and Governance - Irenic Capital is advocating for a board refreshment to include directors with medical OEM experience and financial expertise, as many current directors have been on the board for over 10 years [8] - The current board's composition may hinder the ability to make transformative decisions regarding the company's future [8][9]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decrease of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Investors with significant losses in Integer Holdings Corporation have until February 9, 2026, to file lead plaintiff applications in a securities class action lawsuit due to alleged failure to disclose material information during the Class Period [1][3]. Company Information - Integer Holdings Corporation is facing a class action lawsuit for not disclosing critical information, which is a violation of federal securities laws [3]. - The lawsuit is currently pending in the United States District Court for the Southern District of New York [1]. Financial Performance - On October 23, 2025, Integer disclosed a reduced full-year 2025 sales guidance of $1.840 billion to $1.854 billion, which is significantly below analysts' expectations [4]. - The company also projected net sales growth of -2% to 2% and organic sales growth of 0% to 4% for the full year of 2026, attributed to slower-than-expected market adoption of its products [4]. Stock Price Impact - Following the announcement of the lowered sales guidance, Integer's share price dropped by $35.22, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5] - It is claimed that Integer misrepresented its sales and growth prospects, leading to investor damages when the true situation was revealed [5]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during the specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025, inclusive [1]. - Investors who purchased Integer common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a deterioration in sales for two of its electrophysiology devices [5]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Integer common stock between July 25, 2024, and October 22, 2025, with a deadline of February 9, 2026, for investors to apply as lead plaintiffs [2]. - Allegations include that the company overstated its competitive position, misrepresented customer demand visibility, and mischaracterized its EP devices as growth drivers, leading to materially false and misleading statements about its business [3]. Group 2: Next Steps for Investors - Investors who suffered losses and wish to learn more about the claims or have questions can contact the law firm directly without any cost or obligation [4].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Integer Holdings Corporation (NYSE: ITGR) related to shareholder interests [1]. Group 1: Allegations of Misrepresentation - A federal securities lawsuit claims that insiders at Integer misrepresented the company's competitive position in the expanding EP manufacturing market [2]. - The lawsuit alleges that Integer overstated its visibility into customer demand while actually experiencing a decline in sales for two of its EP devices [2]. - Integer is accused of mischaracterizing its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about the company's business and prospects [2].